Angiotensin Converting Enzyme

Type: Keyphrase
Name: Angiotensin Converting Enzyme
First reported 1 hour ago - Updated 1 hour ago - 1 reports

Congestive Heart Failure Medications

Congestive heart failure medications overviewCongestive heart failure is a chronic (ongoing) condition. Discuss allmedications, herbs, supplements you are taking withyour doctor. Listed are some of the medications used to treat congestiveheart failur ... [Published MedicineNet.com - 1 hour ago]
First reported Oct 25 2014 - Updated Oct 25 2014 - 2 reports

Effects of ACEI/ARB in hypertensive patients with type 2 diabetes mellitus: a meta-analysis of ...

The effects of angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs) on cardiovascular (CV) risk in hypertensive patients with type 2 diabetes mellitus (T2 DM) are uncertain. Our objective was to analyze the effects ... [Published 7thSpace - Oct 25 2014]
First reported Oct 25 2014 - Updated Oct 25 2014 - 1 reports

Ramipril and metoprolol intake aggravate human and murine anaphylaxis: Evidence for direct mast cell priming

Cofactors contribute to the elicitation of anaphylaxis. β-Blockers and angiotensin-converting enzyme (ACE) inhibitors are widely used cardiovascular drugs. We specially designed a mouse model to further analyze the cofactor potential of these drugs. ... [Published Journal of Allergy and Clinical Immunology - Oct 25 2014]
First reported Oct 20 2014 - Updated Oct 20 2014 - 1 reports

A novel aggregation-induced emission based fluorescent probe for an angiotensin converting enzyme (ACE) assay and inhibitor screening

aCollege of Pharmaceutical Sciences, Zhejiang University (Zijingang Campus), Hangzhou, P. R. ChinaE-mail: mysky@zju.edu.cn ;Fax: +86-571-88208426;Tel: +86-571-88208426bCollege of Preclinical Medicine, Zhejiang Chinese Medical University, Hangzhou 310053, ... [Published RSC - Oct 20 2014]
First reported Oct 17 2014 - Updated Oct 17 2014 - 1 reports

Finding out why your kid’s tummy bug might be a bit fishy

A ground breaking study by James Cook University will examine how and why children develop seafood allergies.The Federal Government today announced its National Health and Medical Re Council (NHMRC) would provide six grants to JCU, totalling almost $3.7 ... [Published Noodls - Oct 17 2014]
First reported Oct 14 2014 - Updated Oct 14 2014 - 1 reports

Thoracic Aortic Aneurysm and Dissection

Aortic dissection is the most devastating complication of thoracic aortic disease. In the more than 250 years since thoracic aortic dissection was first described, much has been learned about diseases of the thoracic aorta. In this review, we describe ... [Published Journal of the American College of Cardiology - Oct 14 2014]
First reported Oct 10 2014 - Updated Oct 10 2014 - 1 reports

Sales of heart failure drugs set to soar

Sales of drugs to treat are set to soar, from around $2.9 billion in 2013 to $8.9 billion in 2023, according to new forecasts. Growth in sales of CHF treatments in seven major markets – US, UK, France, Germany, Italy, Spain and Japan – over the period ... [Published Pharma Times - Oct 10 2014]
First reported Oct 09 2014 - Updated Oct 09 2014 - 1 reports

NICE re-evaluates heart failure prescribing practices

Source: MedicImage / AlamyAcute heart failure is responsible for more than 67,000 annual hospital admissions in England and WalesUpdated national guidance on the management of acute heart failure has called into question some common prescribing practices ... [Published Pharmaceutical Journal - Oct 09 2014]
First reported Oct 07 2014 - Updated Oct 07 2014 - 1 reports

A Randomized Controlled Trial of Angiotensin-Converting Enzyme Inhibition for Skeletal Muscle Dysfunction in COPD

BACKGROUND:   Skeletal muscle impairment is a recognized complication of COPD, predicting mortality in severe disease. Increasing evidence implicates the renin-angiotensin system in control of muscle phenotype. We hypothesized that angiotensin-converting ... [Published CHEST - Oct 07 2014]
First reported Oct 03 2014 - Updated Oct 03 2014 - 1 reports

Chronic Heart Failure Market Set to Triple by 2023

Launch of valsartan/sacubitril combo will drive growthDecision Resources Group, a health care research firm located in Burlington, Mass., finds that the chronic heart failure (CHF) market will grow from approximately $2.9 billion in 2013 to $8.9 billion ... [Published P&T Community - Oct 03 2014]
First reported Oct 03 2014 - Updated Oct 03 2014 - 1 reports

Angioedema deaths in US uncommon

Angioedema-related mortality in the United States from 1979 to 2010 was rare, with hereditary angioedema deaths decreasing and nonhereditary angioedema deaths increasing, according to recent study results.The researchers analyzed all US death certificates ... [Published Orthopedics Today - Oct 03 2014]
First reported Sep 28 2014 - Updated Sep 29 2014 - 3 reports

OncoMed's Demcizumab Phase 1b Clinical Trials Show Encouraging Safety and Anti-Tumor Activity at ESMO

Results Support Advancing Demcizumab Into Randomized Phase 2 Clinical TrialsMADRID and REDWOOD CITY, Calif, Sept. 28, 2014 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel therapeutics that target ... [Published Virtual Strategy Magazine - Sep 28 2014]

Quotes

...They generally help relax blood vessels. "Preventing blood vessels from narrowing helps improve blood flow, reduces the backup of blood in the heart and lungs, and decreases the pressure that the heart's left chamber (ventricle) must pump against" WebMD explains
"We know that for certain Australian fish, there have never been any allergy tests for species such as barramundi, for example."
"Based on the data generated from our Phase 1b studies in pancreatic and non-small cell lung cancer we have identified a dosing regimen with impressive anti-tumor activity and an acceptable safety profile. We have confidence that these data enable the advancement of both programs into planned randomized Phase 2 studies in pancreatic cancer and NSCLC.  Results from our Phase 1b demcizumab program not only signal the potential safety and anti-tumor activity for this drug, but also provide encouragement for the potential of an anti-cancer stem cell hypothesis" said Paul J Hastings, Chairman and Chief Executive Officer
Data from the Phase 1b study of demcizumab in NSCLC were presented on September 27 in a poster titled: "A Phase 1b Study of the Anti-Cancer Stem Cell Agent Demcizumab (DEM), Pemetrexed (PEM) & Carboplatin (CARBO) in Patients with First-line Non-Squamous NSCLC" (#1240P)

More Content

All (57) | News (46) | Reports (0) | Blogs (11) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
Congestive Heart Failure Medications [Published MedicineNet.com - 1 hour ago]
How Quality Improvement Links to Real Change in... [Published American Journal of Managed Care - Oct 29 2014]
Canagliflozin and dapagliflozin interactions in... [Published Pharmaceutical Journal - Oct 28 2014]
Treating kidney disease with diet and keto acids [Published thestar.com.my - Oct 26 2014]
Effects of ACEI/ARB in hypertensive patients wi... [Published 7thSpace - Oct 25 2014]
Effects of ACEI/ARB in hypertensive patients wi... [Published BMC - Oct 25 2014]
Ramipril and metoprolol intake aggravate human ... [Published Journal of Allergy and Clinical Immunology - Oct 25 2014]
Evaluation of Collaborative Therapy Review to I... [Published American Journal of Managed Care - Oct 25 2014]
Expert examines contribution of aldosterone in ... [Published Orthopedics Today - Oct 24 2014]
Preventing falls in older people [Published Pharmaceutical Journal - Oct 21 2014]
Aortic Valve Disease [Published General Medicine eJournal - Oct 21 2014]
A novel aggregation-induced emission based fluo... [Published RSC - Oct 20 2014]
NAFLD: A Practical Approach to Treatment [Published General Medicine eJournal - Oct 20 2014]
Blood Pressure Medications: Do They Prevent Hea... [Published NewsMax.com - Oct 19 2014]
Apotex Inc. v. UCB, Inc. [Published JD Supra - Oct 17 2014]
Atherosclerosis risk increased among men with d... [Published Orthopedics Today - Oct 17 2014]
Finding out why your kid’s tummy bug might be a... [Published Noodls - Oct 17 2014]
Reducing heart failure deaths: an interview wit... [Published News-Medical.Net - Oct 16 2014]
Erythropoiesis-Stimulating Agents (ESA) for Pre... [Published Sexual Development - Oct 14 2014]
Thoracic Aortic Aneurysm and Dissection [Published Journal of the American College of Cardiology - Oct 14 2014]
Sales of heart failure drugs set to soar [Published Pharma Times - Oct 10 2014]
NICE re-evaluates heart failure prescribing pra... [Published Pharmaceutical Journal - Oct 09 2014]
How To Clean Your Arteries With One Simple Fruit [Published Epoch Times - Oct 08 2014]
A Randomized Controlled Trial of Angiotensin-Co... [Published CHEST - Oct 07 2014]
Chronic Heart Failure Market Set to Triple by 2023 [Published P&T Community - Oct 03 2014]
Angioedema deaths in US uncommon [Published Orthopedics Today - Oct 03 2014]
Human medicines European public assessment repo... [Published European Medicines Agency - Oct 02 2014]
Kidney Fibrosis Treatment Market: Global Indust... [Published SBWire - Sep 30 2014]
OncoMed's Demcizumab Phase 1b Clinical Trials S... [Published Virtual Strategy Magazine - Sep 28 2014]
OncoMed's Demcizumab Phase 1b Clinical Trials S... [Published Industrial Info Financials - Sep 28 2014]
1 2
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Example of Trial Design Data Relevant for All S... [Published eClinical Trends - Sep 08 2014]
BioCentury  has lead article this week “Betting Big on Hearts” by Emily Cukier-Meisner, Senior Writer, discussing a breakthrough drug for cardiovascular disease developed by Novartis. LCZ696 for heart failure will replace ACE inhibitors widely, so ...
Sacubitril - Valsartan, a "New Threshold of Hop... [Published Health Care Renewal - Sep 03 2014]
Summer must be over, because the next new blockbuster drug appears to be here.  At the end of August, the media heralded the results of a study of a new product for congestive heart failure (CHF) from Novartis. Novartis' New "Game Changer" The New York ...
Angiotensin–Neprilysin Inhibition versus Enalap... [Published NEJM Articles Most Widely Covered in the Press - Sep 03 2014]
Angiotensin-converting–enzyme (ACE) inhibitors have been the cornerstone of the treatment for heart failure and a reduced ejection fraction for nearly 25 years, since enalapril was shown to reduce the risk of death in two trials.1,2 Long-term treatment ...
Angiotensin–Neprilysin Inhibition versus Enalap... [Published The New England Journal of Medicine: Cardiology - Aug 30 2014]
Angiotensin-converting–enzyme (ACE) inhibitors have been the cornerstone of the treatment for heart failure and a reduced ejection fraction for nearly 25 years, since enalapril was shown to reduce the risk of death in two trials. Long-term treatment with ...
Could statins help treat Ebola? [Published AMERICAblog News| A great nation deserves the t ... - Aug 18 2014]
In an article in the New York Times , two physicians propose using drugs that are currently available to treat Ebola. Ebola causes a derangement in endothelial cells (cells lining blood vessels), and this can lead to decreased ability of the patient’s ...
1 2 3
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.